Innate Pharma at the Jefferies Global Healthcare Conference

Innate Pharma, a biotechnology company specializing in cancer immunotherapies, announces its participation in the Jefferies Global Healthcare Conference, which will be held in New York from June 2 to 4, 2026. Innate Pharma, listed on Euronext Paris and Nasdaq, is active in the clinical development of innovative therapeutic antibodies.

Members of the management team will participate in individual meetings to discuss their portfolio of differentiated assets. These include IPH4502, an antibody-drug conjugate for solid tumors, and lacutamab, a monoclonal antibody for T-cell lymphomas. A collaboration with AstraZeneca is also mentioned for monalizumab in lung cancer.